what other glp 1 drugs are there to Make of the GLP-1 Coverage and Cost Landscape GLP-1 Receptor Agonists and Other

Support teams trained in both technical troubleshooting and safer-play conversations help resolve issues quickly while reinforcing healthy habits

Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, emphasized the importance of new treatment options

Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess primary (MACE) and secondary outcomes (all-cause mortality, CV death, non-fatal MI, non-fatal stroke, and HF hospitalisation) between the two treatment groups

The approach to switching should be individualised, based on considerations such as the duration of treatment with, and dose of, the previous GLP1RA and the patient's experience especially with GI symptoms when they initiated the prior therapy

NICE guidance including Technology Appraisal TA875 (semaglutide 2.4 mg for managing overweight and obesity), Clinical Guideline CG189 (Obesity: identification, assessment and management), and Public Health Guidance PH53 (Weight management: lifestyle services for overweight or obese adults) recommends a structured, tiered approach to weight management